Last reviewed · How we verify
oseltamivir and chinese medicinal herbs
Oseltamivir inhibits viral neuraminidase to prevent influenza virus release, while Chinese medicinal herbs provide adjunctive immunomodulatory and anti-inflammatory support.
Oseltamivir inhibits viral neuraminidase to prevent influenza virus release, while Chinese medicinal herbs provide adjunctive immunomodulatory and anti-inflammatory support. Used for Influenza A and B infection treatment and prophylaxis.
At a glance
| Generic name | oseltamivir and chinese medicinal herbs |
|---|---|
| Sponsor | Capital Medical University |
| Drug class | Neuraminidase inhibitor combined with herbal supplement |
| Target | Influenza viral neuraminidase; herbal targets unknown |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Oseltamivir is a neuraminidase inhibitor that blocks the sialic acid receptor on host cells, preventing the release of newly formed influenza virions. The addition of Chinese medicinal herbs (specific composition not standardized in this combination) is intended to enhance immune response and reduce inflammatory symptoms associated with influenza infection, though the exact active components and mechanisms of the herbal component are not well-characterized in conventional pharmacology.
Approved indications
- Influenza A and B infection treatment and prophylaxis
Common side effects
- Nausea
- Vomiting
- Abdominal pain
- Headache
- Neuropsychiatric events (rare)
Key clinical trials
- Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) : Multi-centre, Prospective, Randomized Controlled Study (PHASE4)
- Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1)Pneumonia: Multi-centre, Prospective, Randomized Controlled Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: